Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Cell Mol Life Sci ; 80(1): 33, 2023 Jan 07.
Artigo em Inglês | MEDLINE | ID: mdl-36609925

RESUMO

The question how proteins fold is especially pointed for large multi-domain, multi-spanning membrane proteins with complex topologies. We have uncovered the sequence of events that encompass proper folding of the ABC transporter CFTR in live cells by combining kinetic radiolabeling with protease-susceptibility assays. We found that CFTR folds in two clearly distinct stages. The first, co-translational, stage involves folding of the 2 transmembrane domains TMD1 and TMD2, plus one nucleotide-binding domain, NBD1. The second stage is a simultaneous, post-translational increase in protease resistance for both TMDs and NBD2, caused by assembly of these domains onto NBD1. Our assays probe every 2-3 residues (on average) in CFTR. This in-depth analysis at amino-acid level allows detailed analysis of domain folding and importantly also the next level: assembly of the domains into native, folded CFTR. Defects and changes brought about by medicines, chaperones, or mutations also are amenable to analysis. We here show that the well-known disease-causing mutation F508del, which established cystic fibrosis as protein-folding disease, caused co-translational misfolding of NBD1 but not TMD1 nor TMD2 in stage 1, leading to absence of stage-2 folding. Corrector drugs rescued stage 2 without rescuing NBD1. Likewise, the DxD motif in NBD1 that was identified to be required for export of CFTR from the ER we found to be required already upstream of export as CFTR mutated in this motif phenocopies F508del CFTR. The highly modular and stepwise folding process of such a large, complex protein explains the relatively high fidelity and correctability of its folding.


Assuntos
Regulador de Condutância Transmembrana em Fibrose Cística , Fibrose Cística , Humanos , Regulador de Condutância Transmembrana em Fibrose Cística/metabolismo , Estrutura Terciária de Proteína , Fibrose Cística/genética , Mutação , Peptídeo Hidrolases/genética , Dobramento de Proteína
2.
Ned Tijdschr Geneeskd ; 1662022 01 12.
Artigo em Holandês | MEDLINE | ID: mdl-35138705

RESUMO

With the development of organoids as three-dimensional model organs it is now possible to mimic the growth of human organs in a culture dish. As these model organs can be generated from patients' (diseased) tissue and capture the (genetic) properties thereof, they are more representative disease models than cell lines and animal models. The use of organoids in pathophysiological research has already increased our understanding of many human diseases. Furthermore, organoids are used for patient-specific drug tests for cystic fibrosis, and this will soon be possible for other genetic diseases. Also, transplantation of (own genetically corrected) organoids could become a new treatment option. To fully employ the potential of organoids in medicine, cultures need to be standardized and further optimized for better organ/disease representation. With this, organoids hold the promise to quickly revolutionize personalized and regenerative medicine.


Assuntos
Organoides , Medicina Regenerativa , Animais , Humanos , Organoides/metabolismo , Medicina Regenerativa/métodos
3.
J Mol Biol ; 433(13): 166955, 2021 06 25.
Artigo em Inglês | MEDLINE | ID: mdl-33771570

RESUMO

ABC transporters transport a wealth of molecules across membranes and consist of transmembrane and cytosolic domains. Their activity cycle involves a tightly regulated and concerted domain choreography. Regulation is driven by the cytosolic domains and function by the transmembrane domains. Folding of these polytopic multidomain proteins to their functional state is a challenge for cells, which is mitigated by co-translational and sequential events. We here reveal the first stages of co-translational domain folding and assembly of CFTR, the ABC transporter defective in the most abundant rare inherited disease cystic fibrosis. We have combined biosynthetic radiolabeling with protease-susceptibility assays and domain-specific antibodies. The most N-terminal domain, TMD1 (transmembrane domain 1), folds both its hydrophobic and soluble helices during translation: the transmembrane helices pack tightly and the cytosolic N- and C-termini assemble with the first cytosolic helical loop ICL1, leaving only ICL2 exposed. This N-C-ICL1 assembly is strengthened by two independent events: (i) assembly of ICL1 with the N-terminal subdomain of the next domain, cytosolic NBD1 (nucleotide-binding domain 1); and (ii) in the presence of corrector drug VX-809, which rescues cell-surface expression of a range of disease-causing CFTR mutants. Both lead to increased shielding of the CFTR N-terminus, and their additivity implies different modes of action. Early assembly of NBD1 and TMD1 is essential for CFTR folding and positions both domains for the required assembly with TMD2. Altogether, we have gained insights into this first, nucleating, VX-809-enhanced domain-assembly event during and immediately after CFTR translation, involving structures conserved in type-I ABC exporters.


Assuntos
Regulador de Condutância Transmembrana em Fibrose Cística/química , Regulador de Condutância Transmembrana em Fibrose Cística/metabolismo , Citosol/metabolismo , Biossíntese de Proteínas , Dobramento de Proteína , Aminopiridinas/farmacologia , Benzodioxóis/farmacologia , Regulador de Condutância Transmembrana em Fibrose Cística/biossíntese , Evolução Molecular , Genes Supressores , Células HEK293 , Células HeLa , Humanos , Modelos Moleculares , Peptídeo Hidrolases/metabolismo , Biossíntese de Proteínas/efeitos dos fármacos , Domínios Proteicos , Dobramento de Proteína/efeitos dos fármacos , Estrutura Secundária de Proteína
4.
J Clin Invest ; 129(12): 5236-5253, 2019 12 02.
Artigo em Inglês | MEDLINE | ID: mdl-31657788

RESUMO

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR), with approximately 90% of patients harboring at least one copy of the disease-associated variant F508del. We utilized a yeast phenomic system to identify genetic modifiers of F508del-CFTR biogenesis, from which ribosomal protein L12 (RPL12/uL11) emerged as a molecular target. In the present study, we investigated mechanism(s) by which suppression of RPL12 rescues F508del protein synthesis and activity. Using ribosome profiling, we found that rates of translation initiation and elongation were markedly slowed by RPL12 silencing. However, proteolytic stability and patch-clamp assays revealed RPL12 depletion significantly increased F508del-CFTR steady-state expression, interdomain assembly, and baseline open-channel probability. We next evaluated whether Rpl12-corrected F508del-CFTR could be further enhanced with concomitant pharmacologic repair (e.g., using clinically approved modulators lumacaftor and tezacaftor) and demonstrated additivity of these treatments. Rpl12 knockdown also partially restored maturation of specific CFTR variants in addition to F508del, and WT Cftr biogenesis was enhanced in the pancreas, colon, and ileum of Rpl12 haplosufficient mice. Modulation of ribosome velocity therefore represents a robust method for understanding both CF pathogenesis and therapeutic response.


Assuntos
Regulador de Condutância Transmembrana em Fibrose Cística/genética , Mutação , Ribossomos/metabolismo , Aminopiridinas/farmacologia , Animais , Benzodioxóis/farmacologia , Brônquios/metabolismo , Colo/metabolismo , Regulador de Condutância Transmembrana em Fibrose Cística/química , Epitélio/metabolismo , Feminino , Inativação Gênica , Células HEK293 , Humanos , Íleo/metabolismo , Indóis/farmacologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Proteínas Mutantes/química , Proteínas Mutantes/genética , Pâncreas/metabolismo , Técnicas de Patch-Clamp , Conformação Proteica , Dobramento de Proteína , Ratos , Proteínas Ribossômicas/metabolismo
5.
Curr Opin Pharmacol ; 34: 83-90, 2017 06.
Artigo em Inglês | MEDLINE | ID: mdl-29055231

RESUMO

Pharmacological intervention to treat the lethal genetic disease cystic fibrosis has become reality, even for the severe, most common folding mutant F508del CFTR. CFTR defects range from absence of the protein, misfolding that leads to degradation rather than cell-surface localization (such as F508del), to functional chloride-channel defects on the cell surface. Corrector and potentiator drugs improve cell-surface location and channel activity, respectively, and combination therapy of two correctors and a potentiator have shown synergy. Several combinations are in the drug-development pipeline and although the primary defect is not repaired, rescue levels are reaching those resembling a cure for CF. Combination therapy with correctors may also improve functional CFTR mutants and benefit patients on potentiator therapy.


Assuntos
Regulador de Condutância Transmembrana em Fibrose Cística/metabolismo , Fibrose Cística/tratamento farmacológico , Fibrose Cística/metabolismo , Humanos , Dobramento de Proteína
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA